



Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.

NEW BRUNSWICK, N.J., Dec 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --

Johnson & Johnson (NYSE: JNJ) today announced the completion of its previously announced acquisition of Omrix Biopharmaceuticals, Inc., a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products. Omrix is expected to operate as a stand-alone entity reporting through ETHICON, Inc., a Johnson & Johnson company.

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 119,400 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

SOURCE Johnson & Johnson

<http://www.jnj.com>

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX